1. Home
  2. VYGR vs TCI Comparison

VYGR vs TCI Comparison

Compare VYGR & TCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYGR
  • TCI
  • Stock Information
  • Founded
  • VYGR 2013
  • TCI 1983
  • Country
  • VYGR United States
  • TCI United States
  • Employees
  • VYGR N/A
  • TCI N/A
  • Industry
  • VYGR Biotechnology: Pharmaceutical Preparations
  • TCI Real Estate
  • Sector
  • VYGR Health Care
  • TCI Finance
  • Exchange
  • VYGR Nasdaq
  • TCI Nasdaq
  • Market Cap
  • VYGR 222.9M
  • TCI 248.2M
  • IPO Year
  • VYGR 2015
  • TCI N/A
  • Fundamental
  • Price
  • VYGR $3.39
  • TCI $28.24
  • Analyst Decision
  • VYGR Strong Buy
  • TCI
  • Analyst Count
  • VYGR 9
  • TCI 0
  • Target Price
  • VYGR $14.86
  • TCI N/A
  • AVG Volume (30 Days)
  • VYGR 360.5K
  • TCI 1.7K
  • Earning Date
  • VYGR 03-11-2025
  • TCI 03-20-2025
  • Dividend Yield
  • VYGR N/A
  • TCI N/A
  • EPS Growth
  • VYGR N/A
  • TCI N/A
  • EPS
  • VYGR N/A
  • TCI 0.68
  • Revenue
  • VYGR $80,001,000.00
  • TCI $47,778,000.00
  • Revenue This Year
  • VYGR N/A
  • TCI N/A
  • Revenue Next Year
  • VYGR $23.46
  • TCI N/A
  • P/E Ratio
  • VYGR N/A
  • TCI $41.62
  • Revenue Growth
  • VYGR N/A
  • TCI N/A
  • 52 Week Low
  • VYGR $3.56
  • TCI $25.50
  • 52 Week High
  • VYGR $10.66
  • TCI $37.51
  • Technical
  • Relative Strength Index (RSI)
  • VYGR 28.74
  • TCI 48.55
  • Support Level
  • VYGR $3.58
  • TCI $28.00
  • Resistance Level
  • VYGR $3.96
  • TCI $29.18
  • Average True Range (ATR)
  • VYGR 0.25
  • TCI 0.60
  • MACD
  • VYGR -0.01
  • TCI -0.05
  • Stochastic Oscillator
  • VYGR 2.60
  • TCI 22.22

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About TCI Transcontinental Realty Investors Inc.

Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.

Share on Social Networks: